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euroleptic Malignant Syndrome 
(NMS) is a rare fatal medical 
complication that occurs as a result 
of dopaminergic receptor blockage in the 
caudate at the termination of the nigrostriatal 
pathways (1), and may occur at any time 
following consumption of dopamine 
antagonists. This disorder also occurs in cases 
of sudden discontinuation of dopamine 
agonists and antagonists (2,3). Some studies 
have also reported the syndrome following 
tricyclic antidepressants (TCAs) or specific 
serotonin reuptake inhibitors (SSRIs) use (4). 
The syndromes manifestations are high 
fever, extra-pyramidal symptoms, and 
dysfunctions in autonomic system, such as 
unstable blood pressure, cardiac arrhythmia, 
dyspnea,sweating, and urinary incontinence(5). 
The incidence has been reported from 0.69 
to 3.23percent (6,7). 
A review of 16 studies by Carrof, has 
reported incidence rates of 0.196% (8). In 
another study on 7, 8708 individuals who 
were taking dopamine antagonists, NMS 
occurred in 19 cases; in which the incidence 
rate was 0.024% (9). 
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According to several studies, the NMS 
incidence rates have decreased during the 
recent years (6, 10-13); a 7 time decrease was 
reported in one study (10). 
However, few researchers including 
Adityanjee et al. believe in factors such as 
limitations in study designs as the main 
reason for the decrease in incidence reports 
(11). Also, early diagnosis and treatment must 
be considered as another reason for the 
incidence decline (11). The incidence risk 
following atypical anti-psychotic drugs is 
much lower compare to typical ones. The 
increasing use of antipsychotic drugs reduces 
the MNS incidence as well (14). 
Early diagnosis and treatment of the 
disorder is important. There are several 
reports of NMS following the use of atypical 
anti-psychotics including risperidone (15), 
clozapine(15), olanzapine(15,16) and quetiapine 
(17). Specially atypical presentations have 
been reported with clozapine (18) and 
olanzapine (19). Furthermore, the emergence 
of NMS with other medications such as TCAs 
and SSRIs along with high mortality rate of 
the syndrome (4), have brought the early 
interventions into special importance. 
The following case is reported because 
there are only few reports of NMS with 
clozapine, and also due to atypical 
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who had been receiving treatment for 
paranoid schizophrenia (according to DSM-
IV-TR) with several admissions for the past 
five years. 
He was admitted due to a relapse to a 
psychiatric hospital in Tehran in May 2007. 
There were no history of any noticeable 
physical problems and the results of all 
laboratory tests were normal. He was on 
clozapine for 3.5 months, when the problem 
presented. He was taking clozapine, 400 mg 
daily and clonidine 0.2 mg daily in August 
2007, at the time of NMS emergence. First, he 
had a fever of 38.2 degrees centigrade, 
sweating, drooling and mild rigidity in 
extremities, followed by a decrease in the 
level of consciousness (GCS= 6-7) and only 
responsive to painful stimuli. The blood 
pressure was 100/60 mmHg, pulse rate 110-
120/ min. The CTscan was normal and the 
results of laboratory investigations were as 
follows: 
Serum sodium (Na), potassium (K), 
aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), bilirubine and 
fasting blood sugar (FBS) level were in 
normal range; Patient’s serum creatine 
phosphokinase (CPK) level was 1240 IU/L, 
serum lactic dehydrogenase (LDH) 645 IU/L, 
and white blood cell (WBC) count of 
9000/mm3. The differential diagnoses of 
NMS such as heat stroke, metabolic tetanus, 
septicemia, CNS infection were ruled out 
clinically. Clozapine was discontinued while 
hydration and dantrolene 80mg qid started. 
The body temperature became normal after 3 
days and the level of consciousness increased. 
LDH equaled 318 IU/L and CPK 800 IU/L 





In summary, the patient had a severe 
decline in the level of consciousness, mild 
muscular rigidity, fever, drooling, sweating, 
elevated blood pressure, but no instability in 
autonomic function. NMS was diagnosed 
according to DSM-IV-TR in which the 
disorder is defined by the presence of severe 
muscle rigidity, elevated temperature, and 
other related findings (e.g., diaphoresis, 
dysphagia, incontinence, changes in level of 
consciousness ranging from confusion to coma, 
mutism, elevated or labile blood pressure, 
elevated creatine phosphokinase (20). Although 
the NMS criteria are specific, the presentation 
of this disorder is so variable, that needs 
further precise clinical investigations (21). 
However, fever and muscular rigidity are 
the most accepted symptoms in various studies. 
Our case presented both of theses symptoms, 
along with meeting other criteria (20). 
Some clinicians have suggested NMS 
variants. In specific conditions called 
"atypical" formes frustes and incipient NMS, 
the patient may present most, but not all of 
the symptoms. The idea of the disorder 
variants was introduced from the beginning of 
NMS definition (21). The rigidity only in 
extremities instead of general muscular 
rigidity, observed in our case was also a 
variant symptom. 
The important unanswered question is 
whether NMS is a spectrum of a different 
presentation. 
Our case showed inconsistent symptoms 
and signs such as mildness of extra pyramidal 
symptoms and muscular rigidity. In other 
studies with clozapine, the clinical presentations 
including extra pyramidal symptoms were 
found to be less prominent as well (18,22). In 
one study, muscular rigidity was present in 
36% of cases receiving clozapine (23), while it 
was reported to be 97-98% in previous studies 
(8, 24, 25). 
A study by. Hasan and Buckley showed 
that clinical presentations are the same 
following administration of typical and 
atypical anti-psychotic medications, but CPK 
rises more with the typical anti-psychotics 
(22); a finding which was inconsistent with 
other investigations (26). 
Carrof et al. in 2000 found that fever and 
other presentations are milder in NMS, following 
atypical anti-psychotics (27). Similarly, our 
case showed a low level of fever and mild 
extra pyramidal symptoms. Moreover, at 
anytime following the consumption of 
clozapine the disorder may occur. There are 
reports of the disorder 10 and 30 years after 
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As previously stated, although NMS 
occurs less frequently with the atypical anti-
psychotics, it appears its incidence is 
increasing with more prescriptions of these 
drugs (14). Perhaps the increase is due to the 
rise in atypical forms of the disease (29) 
caused by different therapeutic mechanisms 
of the modern medications (30). 
A review by Hasan and Buckley, of 19 
studies regarding NMS with clozapine and 13 
with risperidone, discovered that 9 cases 
(47%) with clozapine and 8 cases (62%) with 
risperidone met the NMS criteria (22). This 
indicates that NMS induced by atypical anti-
psychotics has atypical or partial presentations 
(11, 22, 27, 29-31). This has been confirmed by 
several studies. The atypical types are as 
hazardous as the typical ones, thus, in need of 
careful clinical diagnosis (29). 
However, it should be noted that NMS of 
typical anti-psychotics might also be variable 
or heterogeneous (27). A few authors believe 
that the partial forms are prevalent, making 
psychiatrists aware of early intervention for 
the problem (22, 27, 31). 
It seems that there have been many 
atypical cases similar to our case that might 
have been missed due to mild presentations 
and incomplete meeting of DSM-IV criteria 
for the disorder (29). The theory implies that 
the atypical forms would develop to typical 
NMS if not intervened properly. 
In conclusion, NMS includes a spectrum of 
symptoms and signs which implies the need 
for a revision to the diagnostic criteria. The 
disorder overlaps with multiple CNS problems 
such as serotonin syndrome, malignant 
hyperthermia and lethal catatonia. The severe 
Serotonin syndrome following administration 
of monoamine oxidase inhibitors (MAOIs) 
and other medications, presents with delirium, 
high blood pressure, muscular rigidity and 
high body temperature. 
Malignant hyperthermia, which is a drug 
reaction presents with autonomic instability, 
muscular rigidity and high body temperature. 
Malignant or fatal catatonia is a state of 
catatonia with hyperthermia. 
The similarity between the presentations of 
the above syndromes and NMS, confirms that  
 
the diagnostic criteria of NMS are not specific 
and require a revision. It appears we do not 
have the proper knowledge regarding the 
patho-physiolgy and neurological mechanisms 
of NMS. Therefore, the disorder and all other 
similar syndromes may belong to a broader 
category of CNS problems (29). 
To sum up, we strongly recommend the 
need for further studies regarding proper 
definition of NMS criteria, in order to prevent 
the under diagnosis of the disorder, especially 
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